Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
62.16
+0.48 (+0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Incyte Corp
< Previous
1
2
3
4
5
6
Next >
Incyte to Present at Upcoming Investor Conference
November 09, 2021
From
Incyte
Via
Business Wire
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
November 04, 2021
From
Incyte
Via
Business Wire
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 02, 2021
From
Incyte
Via
Business Wire
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
November 01, 2021
From
Incyte
Via
Business Wire
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
November 01, 2021
From
Incyte
Via
Business Wire
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
October 28, 2021
From
Incyte
Via
Business Wire
Incyte to Report Third Quarter Financial Results
October 13, 2021
From
Incyte
Via
Business Wire
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
October 02, 2021
From
Incyte
Via
Business Wire
Incyte Names New Member to Its Board of Directors
September 28, 2021
From
Incyte
Via
Business Wire
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
September 22, 2021
From
Incyte
Via
Business Wire
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
September 21, 2021
From
Incyte
Via
Business Wire
Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
September 13, 2021
From
Incyte
Via
Business Wire
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
August 26, 2021
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
August 17, 2021
From
Incyte
Via
Business Wire
Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
August 16, 2021
From
Incyte
Via
Business Wire
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 03, 2021
From
Incyte
Via
Business Wire
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
July 23, 2021
From
Incyte Corporation
Via
Business Wire
Incyte to Report Second Quarter Financial Results
July 15, 2021
From
Incyte
Via
Business Wire
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
July 14, 2021
From
Incyte
Via
Business Wire
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 25, 2021
From
Incyte
Via
Business Wire
Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
June 24, 2021
From
Incyte
Via
Business Wire
Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
June 12, 2021
From
Incyte
Via
Business Wire
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
June 11, 2021
From
Incyte Corporation
Via
Business Wire
Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)
June 08, 2021
From
Incyte
Via
Business Wire
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
June 04, 2021
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
June 04, 2021
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
May 20, 2021
From
Incyte
Via
Business Wire
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
May 19, 2021
From
Incyte
Via
Business Wire
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
May 17, 2021
From
Incyte
Via
Business Wire
Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
May 12, 2021
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.